FDA approvals usher in the post-interferon era in HCV

Nat Biotechnol. 2014 Jan;32(1):3-5. doi: 10.1038/nbt0114-3.
No abstract available

Publication types

  • News

MeSH terms

  • Drug Approval / legislation & jurisprudence
  • Drug Industry / legislation & jurisprudence
  • Hepacivirus / drug effects*
  • Hepacivirus / pathogenicity
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Simeprevir
  • Sofosbuvir
  • Sulfonamides / therapeutic use*
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence
  • Uridine Monophosphate / analogs & derivatives*
  • Uridine Monophosphate / therapeutic use

Substances

  • Heterocyclic Compounds, 3-Ring
  • Sulfonamides
  • Simeprevir
  • Uridine Monophosphate
  • Sofosbuvir